Precision biosciences inc stock.

Dec 1, 2023 · Earnings for Precision BioSciences are expected to grow in the coming year, from ($0.29) to ($0.21) per share. Precision BioSciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off prior year's report dates. Read More. Precision BioSciences, Inc. Common Stock (DTIL) Stock Price, Quote, News & History | Nasdaq MY QUOTES: DTIL Edit my quotes Precision BioSciences, Inc. Common Stock (DTIL)... Get the latest Precision BioSciences, Inc. (DTIL) stock news and headlines to help you in your trading and investing decisions. Mullen Automotive, Inc. Common Stock. $0.2205 +0.0496 29.02%. Precision BioSciences, Inc. Common Stock (DTIL) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US ...

Dec 1, 2023 · A high-level overview of Precision BioSciences, Inc. (DTIL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to fund planned op... SOUTH SAN FRANCISCO, Calif., March 7, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasda...Precision BioSciences Announces $50 Million Offering of Common Stock. June 21, 2022 05:25 PM Eastern Daylight Time. DURHAM, N.C.-- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a ...

Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in …The stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing […]

DTIL | Complete Precision Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an …WebDURHAM, N.C., August 15, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced completion ...Overall market sentiment has been high on Precision BioSciences Inc (DTIL) stock lately. DTIL receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.Web

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

Nov 9, 2023 · On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.

Overall, Precision BioSciences Inc stock has a Value Grade of C, Growth Grade of C, Quality Grade of D, Momentum Grade of F Earnings Estimate Revisions Grade of C. Whether or not you should buy Precision BioSciences Inc stock will ultimately depend on your individual goals, risk tolerance and allocation. AAII can help you figure …In a report released today, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences ( DTIL – Research Report ), with a price target of $6.00. The company’s shares opened today ...Nov 7, 2023 · DURHAM, N.C., November 07, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in ... Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other ...DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.“Our progress in the first …WebPrecision BioSciences, Inc. (NASDAQ:DTIL) shareholders should be happy to see the share price up 15% in the last month. But that is meagre solace in the face of the shocking decline over three years.Web

This free interactive report on Precision BioSciences' balance sheet strength is a great place to start, if you want to investigate the stock further. A Different Perspective. Given that the market gained 5.6% in the last year, Precision BioSciences shareholders might be miffed that they lost 65%.Get the LIVE share price of Precision BioSciences Inc(DTIL) and stock performance in one place to strengthen your trading strategy in US stocks.Precision BioSciences Inc (DTIL) stock is higher by 1.82% while the S&P 500 has fallen -0.2% as of 3:24 PM on Tuesday, Feb 28. DTIL is higher by $0.02 from the previous closing price of $1.10 on volume of 308,757 shares. Over the past year the S&P 500 has fallen -9.14% while DTIL has fallen -73.65%.WebMay 9, 2023 · Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ... H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Precision BioSciences ( DTIL – Research Report) today and set a price target of $17.00. The company’s shares opened today at ...

Revenue. $115.5 million [1] Number of employees. 192 [2] (2022) Website. precisionbiosciences .com. Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. [3] Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using ...Precision BioSciences Inc share price live 0.4366, this page displays NASDAQ DTIL stock exchange data. View the DTIL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Precision BioSciences Inc real time stock price chart below ...

Under the terms of the agreement, Precision will receive an upfront cash payment of $100 million, as well as an equity investment by Lilly of $35 million in Precision's common stock. Precision is also eligible to receive up to $420 million in potential development and commercialization milestones per product, as well as tiered royalties ranging ...Business Wire. DURHAM, N.C., March 27, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T ...DURHAM, N.C., August 15, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today ...Get the latest Precision BioSciences Inc (DTIL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.DTIL | Complete Precision Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Nov 24, 2023 · Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?2.40%. $1.21B. IDYA | Complete IDEAYA Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Get a real-time Precision BioSciences, Inc. (DTIL) stock price quote with breaking news, financials, statistics, charts and more.

We credit much of our successes not only to our technical know-how, but our commitment to our team and our culture. Precision BioSciences utilizes its proprietary ARCUS Genome Editing method to overcome cancers, cure genetic diseases, and enable development of safer food.

Aug 8, 2023 · ARCUS is a precise and versatile genome editing technology discovered and developed by scientists at Precision BioSciences. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases to insert (knock in), remove (knock out), or repair DNA of living cells and tissues. Learn more about ARCUS Genome Editing › Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to ...Discover historical prices for DTIL stock on Yahoo Finance. View daily, weekly or monthly format back to when Precision BioSciences, Inc. stock was issued. Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS …WebThe stock of Precision Biosciences Inc (NASDAQ: DTIL) has decreased by -9.31 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -11.84% in its stock price over the last five trading days. Business Wire reported 2023-10-23 that DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. …BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing ...Get the LIVE share price of Precision BioSciences Inc(DTIL) and stock performance in one place to strengthen your trading strategy in US stocks.Find the latest Precision BioSciences, Inc. (PBS.F) stock quote, history, news and other vital information to help you with your stock trading and investing.Complete Precision Biosciences Inc. stock information by Barron's. View real-time DTIL stock price and news, along with industry-best analysis.

Common stock . This is an initial public offering of shares of common stock by Precision BioSciences, Inc. We are offering shares of our common stock. The initial public offering price is expected to be between $ and $ per share. Prior to this offering, there has been no public market for our common stock.H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Precision BioSciences ( DTIL – Research Report) today and set a price target of $17.00. The company’s shares opened today at ...Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market Oct 26 Price target decreased by 15% to US$2.60Jun 22, 2023 · Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 From $11, Maintains Buy Rating. Goldman Sachs Adjusts Precision BioSciences' Price Target to $2 From $3, Keeps Neutral Rating. More news. Press releases Precision BioSciences, Inc. Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update. Instagram:https://instagram. elli lilly stocknvda stock stocktwitsbest 529 accountus 6 month treasury 15 thg 8, 2023 ... ... stock price, and other important factors discussed under the caption ... precision biosciences, inc. is a biotechnology company located in ... toggle pet insurancetrading analytics software Precision BioSciences Stock (NASDAQ: DTIL) stock price, news, charts, stock research, profile.(RTTNews) - Neurocrine Biosciences Inc (NBIX) announced a profit for first quarter that decreased from last year and missed the Street estimates.... (RTTNews) - Neurocrine Biosciences Inc (NBIX) announced a profit for first quarter that de... best real estate investment sites Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform.Precision BioSciences, Inc. 302 East Pettigrew Street Suite A-100 Durham, NC 27701 United States 919 314 5512 https://www.precisionbiosciences.com Sector(s) : Healthcare Industry : Biotechnology ...About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life ... risks related to ownership of our common stock; ...